A phase Ib/II study evaluating nivolumab in combination with azacytidine in patients with relapsed acute myeloid leukemia.

Trial Profile

A phase Ib/II study evaluating nivolumab in combination with azacytidine in patients with relapsed acute myeloid leukemia.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Azacitidine (Primary) ; Nivolumab (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Jul 2017 New trial record
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top